Your session is about to expire
← Back to Search
Study Summary
This trial studies a drug to treat Lupus Nephritis in people who haven't responded to other treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 1 & 2 trial • 91 Patients • NCT01421186Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are seniors (60+ years old) being considered for participation in this clinical research?
"Individuals aged 18-75 are eligible to participate in this trial. Subgroups of 12 minors and 42 seniors have been identified for specialized study protocols."
How can Felzartamab be administered without adverse effects?
"The safety of Felzartamab is rated as a 1 according to our team at Power, which reflects its status in Phase 1 trials with limited data supporting efficacy and security."
What is the upper threshold of participants for this research project?
"Affirmative. According to the information stored on clinicaltrials.gov, this clinical trial is actively looking for participants and was first posted on October 1st 2023 with its latest edit occurring a month later. The enrollment goal of this study is 20 patients from one medical site."
Is there a possibility to enroll in this research endeavor presently?
"Affirmative. Currently posted on clinicaltrials.gov, this medical research is actively enrolling participants according to the information provided when it was initially uploaded on October 1st 2023 and revised by October 23rd of the same year. This study requires that 20 patients be recruited from one location."
To whom is this trial open for enrollment?
"This research endeavour is currently attempting to enrol 20 eligible persons with Systemic Lupus Erythematosus (SLE) and International Society of Nephrology/ Renal Pathology Society (ISN/RPS) 2003 Class III or IV LN. Recipients must be between 18-75 years old, have a urine protein:creatinine ratio above 1 g/g, an estimated glomerular filtration rate that surpasses 45 mL/min per 1.73 meters squared, and evidence of inadequate response or intolerance to at least 3 months of conventional care for lupus nephritis."
Share this study with friends
Copy Link
Messenger